← Back to headlines
Immunic Secures $400M Financing for Phase 3 MS Data Readout
Immunic has secured $400 million in financing, setting the stage for the readout of its phase 3 multiple sclerosis (MS) data.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
